Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 10, 2025
DataAggregated Company Financials
Companies548
  • 7D1.1%
  • 3M8.5%
  • 1Y-5.8%
  • YTD7.6%

The Biotech industry is up 1.1% in the last week, with Alnylam Pharmaceuticals up 7.9%. In contrast, the industry has lost 5.8% in the last 12 months. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 11 Sep 2025US$1.1tUS$163.6b-US$18,332,951,430.5415.3x-59.3x6.6x
Sat, 09 Aug 2025US$1.0tUS$162.9b-US$15,182,045,228.3613.2x-66.3x6.2x
Mon, 07 Jul 2025US$960.2bUS$155.8b-US$23,415,675,000.5617.3x-41x6.2x
Wed, 04 Jun 2025US$922.8bUS$155.9b-US$23,951,572,272.4415.9x-38.5x5.9x
Fri, 02 May 2025US$808.2bUS$119.4b-US$30,863,458,745.1220.6x-26.2x6.8x
Sun, 30 Mar 2025US$816.7bUS$118.6b-US$36,963,437,893.6024.4x-22.1x6.9x
Tue, 25 Feb 2025US$863.5bUS$117.3b-US$37,621,182,300.4716.8x-23x7.4x
Thu, 23 Jan 2025US$968.7bUS$149.5b-US$26,308,060,833.4017.3x-36.8x6.5x
Sat, 21 Dec 2024US$947.6bUS$149.9b-US$26,392,835,378.3815.2x-35.9x6.3x
Mon, 18 Nov 2024US$991.1bUS$150.0b-US$26,801,381,083.8817.2x-37x6.6x
Wed, 16 Oct 2024US$905.5bUS$113.1b-US$36,033,769,973.8221.7x-25.1x8x
Fri, 13 Sep 2024US$906.6bUS$113.2b-US$35,840,476,743.7522.7x-25.3x8x
Sun, 11 Aug 2024US$862.3bUS$112.7b-US$36,840,475,721.7821.6x-23.4x7.7x
Tue, 09 Jul 2024US$1.1tUS$164.5b-US$28,072,591,965.7828.2x-40.3x6.9x
Thu, 06 Jun 2024US$1.1tUS$164.6b-US$26,649,807,121.8228.1x-42.6x6.9x
Sat, 04 May 2024US$1.1tUS$163.7b-US$26,731,775,868.3424.3x-41.9x6.8x
Mon, 01 Apr 2024US$1.2tUS$164.4b-US$23,612,220,177.6624x-50x7.2x
Wed, 28 Feb 2024US$1.2tUS$167.3b-US$21,469,811,290.4513.8x-55.3x7.1x
Fri, 26 Jan 2024US$1.4tUS$204.7b-US$22,591,368,127.0018.5x-63.1x7x
Sun, 24 Dec 2023US$1.4tUS$204.9b-US$22,149,017,627.0019.4x-61.9x6.7x
Tue, 21 Nov 2023US$1.2tUS$204.7b-US$22,041,856,134.0018.1x-55.4x6x
Thu, 19 Oct 2023US$1.3tUS$207.3b-US$13,074,578,847.0017.1x-95.7x6x
Sat, 16 Sep 2023US$1.3tUS$207.5b-US$12,636,400,679.0017.6x-101.2x6.2x
Mon, 14 Aug 2023US$1.3tUS$207.7b-US$12,468,580,885.0016.6x-103.3x6.2x
Wed, 12 Jul 2023US$1.1tUS$186.4b-US$16,009,595,226.0013.3x-70.2x6x
Fri, 09 Jun 2023US$1.2tUS$186.1b-US$15,982,663,871.0011.8x-72x6.2x
Sun, 07 May 2023US$1.2tUS$192.6b-US$12,085,119,722.0015.6x-97.1x6.1x
Tue, 04 Apr 2023US$1.2tUS$217.1b-US$5,977,015,471.0014.3x-194.8x5.4x
Thu, 02 Mar 2023US$1.1tUS$199.1b-US$5,117,523,678.0015.3x-222.5x5.7x
Sat, 28 Jan 2023US$1.2tUS$203.8bUS$1.8b14.8x668.4x5.7x
Mon, 26 Dec 2022US$1.2tUS$203.3bUS$1.6b14.5x703x5.7x
Wed, 23 Nov 2022US$1.1tUS$202.1bUS$1.2b14.9x926.5x5.6x
Fri, 21 Oct 2022US$1.0tUS$206.2bUS$5.5b15.6x188.5x5x
Sun, 18 Sep 2022US$1.1tUS$206.6bUS$5.8b14.7x184.6x5.2x
Price to Earnings Ratio

184.6x


Total Market Cap: US$1.1tTotal Earnings: US$5.8bTotal Revenue: US$206.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 36.8x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.5% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.39%
Healthcare1.15%
Biotech1.07%
Biotech1.07%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ALNY Alnylam PharmaceuticalsUS$469.314.9%
+US$2.9b		79.2%PS25x
GILD Gilead SciencesUS$115.252.0%
+US$2.8b		42.4%PE22.7x
EXAS Exact SciencesUS$54.7711.2%
+US$1.0b		-14.6%PS3.5x
CNTA Centessa PharmaceuticalsUS$22.7142.7%
+US$911.7m		65.2%PS203x
ROIV Roivant SciencesUS$13.779.4%
+US$805.8m		11.2%PS404.7x

Latest News

TRML
US$47.60
Tourmaline Bio
7D
89.6%
1Y
165.6%
EXAS
US$54.77
Exact Sciences
7D
11.2%
1Y
-14.6%
ALNY
US$469.31
Alnylam Pharmaceuticals
7D
4.9%
1Y
79.2%
ONC
US$313.93
BeOne Medicines
7D
-6.6%
1Y
48.7%
MLYS
US$38.56
Mineralys Therapeutics
7D
31.8%
1Y
231.3%
REGN
US$555.83
Regeneron Pharmaceuticals
7D
-1.4%
1Y
-51.3%
IONS
US$63.98
Ionis Pharmaceuticals
7D
5.8%
1Y
50.4%
AMGN
US$278.51
Amgen
7D
-1.9%
1Y
-15.6%
BMRN
US$54.50
BioMarin Pharmaceutical
7D
-7.6%
1Y
-35.7%
SMMT
US$18.83
Summit Therapeutics
7D
-21.0%
1Y
-18.0%
ROIV
US$13.77
Roivant Sciences
7D
9.4%
1Y
11.2%
GILD
US$115.25
Gilead Sciences
7D
2.0%
1Y
42.4%
VRTX
US$388.55
Vertex Pharmaceuticals
7D
-2.0%
1Y
-18.2%

Gene Editing And New Therapies Will Transform Global Healthcare

Analysts maintain a cautious-but-constructive stance on Vertex Pharmaceuticals, citing strong CF performance and resilient topline results offset by pipeline setbacks and future revenue concentration risks, with the consensus price target unchanged at $481.04. Analyst Commentary Bullish analysts highlight Vertex’s continued strong execution track record, robust base cystic fibrosis (CF) business, solid Q2 results with topline beats, and a positive long-term growth outlook beyond near-term setbacks.
CAI
US$33.40
Caris Life Sciences
7D
-9.2%
1Y
n/a
CNTA
US$22.71
Centessa Pharmaceuticals
7D
42.7%
1Y
65.2%
ALKS
US$26.93
Alkermes
7D
-10.2%
1Y
1.4%